MedTrace Logo

Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori

NCT06299605 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2024-12-03

No results posted yet for this study

Summary

The study aimed to compare the efficacy and safety of 7-day and 14-day vonoprazan-amoxicillin-tetracycline triple therapy with 14-day vonoprazan-amoxicillin-tetracycline-bismuth quadruple therapy for the eradication of Helicobacter pylori. Subjects were randomized to receive the intervention and were reviewed by 13C-urea breath test after 6 weeks. The eradication rates, adverse reaction rates and patient adherence were calculated.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days

Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days

DRUG

Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days

Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days

DRUG

Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days

Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days

Sponsors & Collaborators

  • Binzhou Maternal and Child Health Hospital

    collaborator UNKNOWN

  • Zibo Maternal and Child Health Hospital

    collaborator UNKNOWN

  • Zaozhuang Municipal Hospital

    collaborator OTHER

  • Linyi Yizhou Hospital

    collaborator UNKNOWN

  • Feicheng Municipal People's Hospital

    collaborator UNKNOWN

  • Shandong University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-27
Primary Completion
2025-10-01
Completion
2025-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06299605 on ClinicalTrials.gov